{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:21:27Z","timestamp":1761895287658},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,5,29]],"date-time":"2011-05-29T00:00:00Z","timestamp":1306627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11060-011-0612-7","type":"journal-article","created":{"date-parts":[[2011,5,28]],"date-time":"2011-05-28T10:13:02Z","timestamp":1306577582000},"page":"523-530","source":"Crossref","is-referenced-by-count":22,"title":["Salvage therapy with single agent bendamustine for recurrent glioblastoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Marc C.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra K.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,29]]},"reference":[{"issue":"8","key":"612_CR1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1517\/13543780903052764","volume":"18","author":"C Adamson","year":"2009","unstructured":"Adamson C, Kanu OO et al (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18(8):1061\u20131083","journal-title":"Expert Opin Investig Drugs"},{"key":"612_CR2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","volume":"345","author":"H Brem","year":"1995","unstructured":"Brem H, Piantadosi S, Burger PC, Walker M, Selker R et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008\u20131012","journal-title":"Lancet"},{"issue":"18","key":"612_CR3","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2009.25.6941","volume":"28","author":"SE Fogh","year":"2010","unstructured":"Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28(18):3048\u20133053","journal-title":"J Clin Oncol"},{"issue":"18","key":"612_CR4","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1200\/JCO.2006.08.1661","volume":"25","author":"KA Carson","year":"2007","unstructured":"Carson KA, Grossman SA et al (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25(18):2601\u20132606","journal-title":"J Clin Oncol"},{"issue":"12","key":"612_CR5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1517\/13543784.16.12.1895","volume":"16","author":"ER Gerstner","year":"2007","unstructured":"Gerstner ER, Duda DG et al (2007) Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs 16(12):1895\u20131908","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"612_CR6","first-page":"E5","volume":"20","author":"LCA Hou","year":"2006","unstructured":"Hou LCA, Veeravagu A et al (2006) Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 20(4):E5","journal-title":"Neurosurg Focus"},{"key":"612_CR7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.1991.9.5.860","volume":"9","author":"WKA Yung","year":"1991","unstructured":"Yung WKA, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant gliomas: a phase II study. J Clin Oncol 9:860","journal-title":"J Clin Oncol"},{"issue":"3","key":"612_CR8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/archneurol.2010.11","volume":"67","author":"FM Iwamoto","year":"2010","unstructured":"Iwamoto FM, Fine HA (2010) Bevacizumab for malignant gliomas. Arch Neurol 67(3):285\u2013288","journal-title":"Arch Neurol"},{"issue":"34","key":"612_CR9","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","volume":"26","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine\u2013glycine\u2013aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610\u20135617","journal-title":"J Clin Oncol"},{"issue":"4","key":"612_CR10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1212\/01.wnl.0000197792.73656.c2","volume":"66","author":"F Schmidt","year":"2006","unstructured":"Schmidt F, Fischer J, Herrlinger U et al (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66(4):587\u2013589","journal-title":"Neurology"},{"issue":"11","key":"612_CR11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1586\/14737140.6.11.1593","volume":"6","author":"L Simpson","year":"2006","unstructured":"Simpson L, Galanis E (2006) Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 6(11):1593\u20131607","journal-title":"Expert Rev Anticancer Ther"},{"issue":"7","key":"612_CR12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","volume":"28","author":"W Wick","year":"2010","unstructured":"Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168\u20131174","journal-title":"J Clin Oncol"},{"issue":"5","key":"612_CR13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00415-009-5006-9","volume":"256","author":"A Wick","year":"2009","unstructured":"Wick A, Pascher C, Wick W et al (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734\u2013741","journal-title":"J Neurol"},{"key":"612_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1215\/S1152851703000607","volume":"6","author":"SJ See","year":"2004","unstructured":"See SJ, Levin VA, Yung A et al (2004) 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-Oncology 6:253\u2013258","journal-title":"Neuro-Oncology"},{"key":"612_CR15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cncr.20072","volume":"100","author":"MC Chamberlain","year":"2004","unstructured":"Chamberlain MC, Tsao-Wei D (2004) Recurrent glioblastoma multiforme: salvage therapy with cyclophosphamide. Cancer 100:1213\u20131220","journal-title":"Cancer"},{"key":"612_CR16","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1200\/JCO.2003.12.097","volume":"21","author":"KA Jaeckle","year":"2003","unstructured":"Jaeckle KA, Hess KR, Yung A et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21:2305\u20132311","journal-title":"J Clin Oncol"},{"issue":"4","key":"612_CR17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/14712598.8.4.541","volume":"8","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ (2008) Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 8(4):541\u2013553","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"612_CR18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","volume":"83","author":"WK Yung","year":"2000","unstructured":"Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588\u2013593","journal-title":"Br J Cancer"},{"issue":"2","key":"612_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-008-9607-4","volume":"89","author":"SE Coombs","year":"2008","unstructured":"Coombs SE, Bischof M, Welzel T et al (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89(2):205\u2013210","journal-title":"J Neurooncol"},{"key":"612_CR20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","volume":"359","author":"PY Wen","year":"2008","unstructured":"Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492\u2013507","journal-title":"N Engl J Med"},{"key":"612_CR21","unstructured":"Park JK, Hodges T, Arko L. et al (2009) Scale to predict survival after surgery for recurrent glioblastoma multiforme. Presented in part at the Annual Meeting of the Congress of Neurological Surgeons, New Orleans, 24\u201329 October 2009"},{"key":"612_CR22","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2009.27.1932","volume":"28","author":"M Brada","year":"2010","unstructured":"Brada M, Stenning S, Gabe R et al (2010) Temozolomide versus procarbazine, lomustine and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601\u20134608","journal-title":"J Clin Oncol"},{"key":"612_CR23","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1200\/JCO.2008.16.7510","volume":"26","author":"DA Reardon","year":"2008","unstructured":"Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine\u2013glycine\u2013aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610\u20135617","journal-title":"J Clin Oncol"},{"issue":"13","key":"612_CR24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1200\/JCO.2006.06.6514","volume":"25","author":"LB Nabors","year":"2007","unstructured":"Nabors LB, Mikkelsen T, Rosenfeld SS et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651\u20131657","journal-title":"J Clin Oncol"},{"issue":"12","key":"612_CR25","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","volume":"28","author":"JR Perry","year":"2010","unstructured":"Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE Study. J Clin Oncol 28(12):2051\u20132057","journal-title":"J Clin Oncol"},{"key":"612_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1215\/15228517-2006-025","volume":"9","author":"KV Ballman","year":"2007","unstructured":"Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncology 9:29\u201338","journal-title":"Neuro-Oncology"},{"key":"612_CR27","first-page":"162","volume":"10","author":"KR Lamborn","year":"2008","unstructured":"Lamborn KR, Yung AWK, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. J Neurooncol 10:162\u2013170","journal-title":"J Neurooncol"},{"key":"612_CR28","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","volume":"17","author":"ET Wong","year":"1999","unstructured":"Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572\u20132578","journal-title":"J Clin Oncol"},{"key":"612_CR29","unstructured":"Bendamustine hydrochloride (CEP-18083) INVESTIGATOR\u2019S BROCHURE, Cephalon Edition 2 Release Date: 4 March 2010"},{"issue":"6","key":"612_CR30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd2596","volume":"7","author":"MJ Keating","year":"2008","unstructured":"Keating MJ, Bach C, Yasothan U, Kirkpatrick P (2008) Bendamustine. Nat Rev Drug Discov 7(6):473\u2013474","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"612_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309\u2013317","journal-title":"Clin Cancer Res"},{"issue":"10","key":"612_CR32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00044011-200424100-00007","volume":"24","author":"W K\u00f6ster","year":"2004","unstructured":"K\u00f6ster W, Stamatis G, Heider A et al (2004) Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Investig 24(10):611\u2013618","journal-title":"Clin Drug Investig"},{"issue":"4","key":"612_CR33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.JTO.0000263714.46449.4c","volume":"2","author":"W K\u00f6ster","year":"2007","unstructured":"K\u00f6ster W, Heider A, Niederle N et al (2007) Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2(4):312\u2013316","journal-title":"J Thorac Oncol"},{"issue":"8","key":"612_CR34","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/CAD.0b013e328165d11a","volume":"18","author":"MH Eichbaum","year":"2007","unstructured":"Eichbaum MH, Schuetz F, Khbeis T et al (2007) Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs 18(8):963\u2013968","journal-title":"Anticancer Drugs"},{"issue":"2","key":"612_CR35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204\u2013210","journal-title":"J Clin Oncol"},{"issue":"2","key":"612_CR36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","volume":"132","author":"T Lissitchkov","year":"2006","unstructured":"Lissitchkov T, Arnaudov G, Peytchev D, Merkle KH (2006) Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132(2):99\u2013104","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"612_CR37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","volume":"26","author":"JW Friedberg","year":"2008","unstructured":"Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204\u2013210","journal-title":"J Clin Oncol"},{"key":"612_CR38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00432-001-0303-4","volume":"128","author":"K Zulkowski","year":"2002","unstructured":"Zulkowski K, Kath R, Semrau R, Merkle KH, H\u00f6ffken K (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128:111\u2013113","journal-title":"J Cancer Res Clin Oncol"},{"key":"612_CR39","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","volume":"8","author":"DR MacDonald","year":"1990","unstructured":"MacDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277\u20131280","journal-title":"J Clin Oncol"},{"issue":"11","key":"612_CR40","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963\u20131972","journal-title":"J Clin Oncol"},{"issue":"9","key":"612_CR41","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Rummel M (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27(9):1492\u20131501","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0612-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0612-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0612-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T09:37:03Z","timestamp":1637746623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0612-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,29]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0612-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,29]]}}}